TITLE

COMMENTARY: Formoterol in addition to tiotropium improved airflow obstruction in chronic obstruction pulmonary disease

AUTHOR(S)
Schünemann, Holger J.
PUB. DATE
September 2006
SOURCE
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents comments on a study by Van Noord and colleagues to find out the effects of the drug formoterol and tiotropium in the treatment of chronic obstructive pulmonary disease. The author observes that the combination therapy adopted by the researchers under controlled experimental conditions improved the pulmonary function of the patients. The author suggests that improvements in these function were small and their importance to patients is not significant.
ACCESSION #
22493483

 

Related Articles

  • Formoterol in addition to tiotropium improved airflow obstruction in chronic obstruction pulmonary disease.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p39 

    The article presents information on a study to find out the effects of formoterol and tiotropium in the treatment of chronic obstructive pulmonary disease. The randomized controlled study was conducted by J.A. Van Noord, J.L. Aumann and E. Janssens. The tests were conducted on 95 patients aged...

  • Acute Effect of Long-Acting Bronchodilators on Thoracic Gas Compression in Patients with COPD. Şen, Elif; Bartu, Sevgi Saryal; Yıldız, Öznur Akkoca; Köse, Kenan // Turk Toraks Dergisi / Turkish Thoracic Journal;Sep2009, Vol. 10 Issue 3, p122 

    Objective: Thoracic gas compression (TGC) has a negative effect on expiratory flow. In patients with chronic obstructive pulmonary disease (COPD), TGC is high. Bronchodilators may affect thoracic gas compression by reducing airway resistance and improve maximal expiratory flow. The aim of this...

  • Moving from the Oslerian paradigm to the postgenomic era: are asthma and COPD outdated terms? Vanfleteren, Lowie E. G. W.; Kocks, Janwillem W. H.; Stone, Ian S.; Breyer-Kohansal, Robab; Greulich, Timm; Lacedonia, Donato; Buhl, Roland; Fabbri, Leonardo M.; Pavord, Ian D.; Barnes, Neil; Wouters, Emiel F. M.; Agusti, Alvar // Thorax;Jan2014, Vol. 69 Issue 1, p72 

    In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally...

  • Lessons From Large Clinical Trials in Managing COPD Patients. Miravitlles, Marc; Anzueto, Antonio // Turk Toraks Dergisi / Turkish Thoracic Journal;Sep2009, Vol. 10 Issue 3, p130 

    Large, multicenter, randomized controlled trials in COPD have recently been completed. The largest of these studies are "Towards a Revolution in COPD Health" (TORCH) and "Understanding Potential Long-Term Impacts on Function with Tiotropium" (UPLIFT®). These studies make considerable...

  • Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.  // Current Medical Literature: Respiratory Medicine;2008, Vol. 22 Issue 3, p79 

    The article discusses research being done on the use of nebulized formoterol in patients with chronic obstructive pulmonary disease (COPD) taking tiotropium. Results showed that both forced expiratory volume and dyspnea have improved following the addition of formoterol. However, the study found...

  • Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial Bölükbas, Servet; Eberlein, Michael; Eckhoff, Jennifer; Schirren, Joachim // European Journal of Cardio-Thoracic Surgery;Jun2011, Vol. 39 Issue 6, p995 

    Abstract: Objective: A new diagnosis of chronic obstructive pulmonary disease (COPD) is often made during the evaluation of patients requiring a surgical intervention for lung cancer. Based on initial impaired lung function, these untreated patients are often considered not fit for lung surgery....

  • Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options. Friedman, M.; Hilleman, D.E. // PharmacoEconomics;Mar2001, Vol. 19 Issue 3, p245 

    The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) is rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees,...

  • COPD inhaler raises cardiac risk. Praities, Nigel // Pulse;1/13/2010, Vol. 70 Issue 1, p13 

    The article discusses the findings of a research study about the impact of short-acting bronchodilator ipratropium for patients with chronic obstructive pulmonary disease (COPD), lead by professor Todd Lee at the Northwestern University in Chicago, Illinois.

  • Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tashkin, Donald P.; Ferguson, Gary T. // Respiratory Research;May2013, Vol. 14 Issue 5, p1 

    Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the classification of patients for treatment...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics